Clinical Trial

An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
This an open-label phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 6 and 10 years after booster dose.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-26.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-01-23
Trial Details
NCT Number NCT06484686
Lead Sponsor Sinovac (Dalian) Vaccine Technology Co., Ltd.
Conditions Varicella
Enrollment 414 participants
Start Date 2024-09-16
Primary Completion 2028-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-27